Does Rallies show 13F holders for IKT?

Yes. Rallies tracks hedge fund and 13F ownership data for IKT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IKT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IKT. It does not provide personalized investment advice.

IKT (Inhibikase Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Inhibikase Therapeutics, Inc. Common Stock (IKT) is a publicly traded Healthcare sector company. As of May 21, 2026, IKT trades at $1.72 with a market cap of $212.57M and a P/E ratio of -3.80. IKT moved +7.64% today. Year to date, IKT is -16.42%; over the trailing twelve months it is -15.58%. Its 52-week range spans $1.13 to $4.20. Analyst consensus is strong buy with an average price target of $6.20. Rallies surfaces IKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IKT stock?

Hedge funds tracked by Rallies that own IKT include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Inhibikase Therapeutics, Inc. Common Stock.

IKT Key Metrics

Key financial metrics for IKT
Metric	Value
Price	$1.72
Market Cap	$212.57M
P/E Ratio	-3.80
EPS	$-0.43
Dividend Yield	0.00%
52-Week High	$4.20
52-Week Low	$1.13
Volume	0
Avg Volume	0
Revenue (TTM)	$3.72M
Net Income	$-50.96M
Gross Margin	0.00%

Top Hedge Funds Holding IKT

Exoduspoint Capital holds 32.54K shares of IKT, changed +0.00% as of Mar 31, 2025.

Latest IKT News

Inhibikase Reports $170.4M Cash, EMA FAST-EU Greenlight for Phase 3 in 16 Countries — May 12, 2026
Inhibikase Grants 685,718 Options at $1.68 with Ten-Year Term — Apr 3, 2026
Inhibikase Initiates Two-Part Phase 3 PAH Trial, Holds $178.8M Cash — Mar 26, 2026
Bank of America Sees 240% Upside for IKT on Infrastructure Financing Boom — Feb 22, 2026

Recent IKT Insider Trades

Sands Capital Life Sciences Pulse Fund II, L.P. bought 2.07M (~$3.00M) on Nov 21, 2025.
Bellini Roberto bought 1.46M (~$2.00M) on Oct 21, 2024.
Kush Arvind bought 145.00K (~$198.65K) on Oct 21, 2024.

IKT Analyst Consensus

5 analysts cover IKT: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.20.

Common questions about IKT

Who owns IKT stock?: Hedge funds tracked by Rallies that own IKT include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Inhibikase Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for IKT?: Yes. Rallies tracks hedge fund and 13F ownership data for IKT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IKT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IKT. It does not provide personalized investment advice.